
Site burden is now measured through satisfaction surveys, in-the-moment check-ins, and adoption patterns, but each method catches a different moment, and the gaps between them decide whether teams can act before burden becomes risk.
CRF Health announced that its TrialMax Touch and TrialMax Slate solutions have been selected by a Global Category Japanese Pharmaceutical company for a pain outcomes study. The Phase III trial will involve 800 screened and 320 randomized subjects across 40 sites in the US.
Read the full release






